Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent
June 25 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Releases "IsoStilbene" Injectable Formulation of
Pterostilbene Under Granted Patent for
Augmentation of Immunotherapy and Targeting of Cancer Stem
Cells
IsoStilbene to be Included in Pan American Cancer
Treatment Center Protocols
Oceanside, CA -- June
25, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions
International, Inc., (OTC
Markets:
TSOI) announced today
the formulation and
initial clinical implementation of an injectable form
of pterostilbene called "IsoStilbene derived from their '047
patent."
As
previously announced TSOI has licensed its entire StemVacs Platform
that includes our peptide pulsed dendritic cell vaccine
(StemVacs),
innaMune, MemoryMune, LymphoBoost, and NanoStilbene to Pan American
Cancer Center ("Pan
Am") in
Tijuana Mexico.
"In
adding IsoStilbene, an injectable formulation of pterostilbene, to
Pan Am' arsenal of immuno-therapeutics, they now have the ability
to provide booster dosing of pterostilbene to supplement the 10ml
daily intake of NanoStilbene patients already receive as part of
their overall treatment, by providing IsoStilbene
intravenously," said Timothy Dixon,
President and CEO of Therapeutic Solutions International. "This is
now the fourth
commercial product
derived from the issued '047 patent and we are very excited to
offer this to Pan Am
as
well," added Mr.
Dixon.
Peer reviewed
publications have demonstrated efficacy of the pterostilbene
molecule
at
stimulating immunity to cancer, as well as targeting cancer stem
cells1,2. Unfortunately,
classical formulations of pterostilbene do not appear to deliver
effective amounts of pterostilbene to cancer
cells. For this reason, Therapeutic Solutions International has
developed several alternative dosing formulations including the
previously disclosed NanoStilbene, and now, IsoStilbene.
"Pterostilbene is a
highly potent analogue of resveratrol, which has been shown by
multiple investigators to possess therapeutic benefits in a variety
of models of cancer. The current progress by the Company, combined
with collaborators at the Pan Am Cancer Treatment Center, allows
for rapid translation of these non-toxic cancer immunotherapeutic
approaches to the clinic," said James
Veltmeyer, MD, Chief Medical Officer of TSOI.
1 Huang et al.
Modulation of macrophage polarization and lung
cancer cell stemness by MUC1 and
development of a related small-molecule inhibitor
pterostilbene. Oncotarget.
2016 Jun 28;7(26):39363-39375. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=8101&pubmed-linkout=1
2 Mak
et
al. Pterostilbene, a bioactive
component of blueberries, suppresses the generation of
breast cancer stem cells within
tumor microenvironment and metastasis via modulating
NF-B/microRNA 448
circuit. Mol
Nutr
Food
Res. 2013
Jul;57(7):1123-34. https://www.ncbi.nlm.nih.gov/pubmed/23504987
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024